Mouse Anti-Human CD79 (B29 Ig)

GWB-25F069

CB3-1

Human CD79/B29/IgCD79 is a 23/21 disulfide-linked heterodimer composed of an chain (CD79a/mb-1) and a chain (CD79b/B29) that associates non-covalently with membrane immunoglobulin to form the B cell receptor (BCR) complex. Its expression is restricted to B lymphocytes first appearing on the surface at the pro-B cell stage and remaining through all stages of B cell differentiation prior to plasma cells. Crosslinking of the BCR leads to B cell activation. The monoclonal antibody CB3-1 reacts with the chain of CD79. ^1-4

Reagents contain sodium azide which is very toxic if ingested or inhaled. Avoid contact with skin eyes or clothing. Wear eye or face protection when handling. If skin or eye contact occurs wash with copious amounts of water. If ingested or inhaled contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Heterodimer of alpha and beta chains; disulfide-linked. Part of the B-cell antigen receptor complex where the alpha/beta chain heterodimer is non-covalently associated with an antigen-specific membrane-bound surface immunoglobulin of two heavy chains and two light chains. Interacts through its phosphorylated ITAM domain with the SH2 domains of SYK which stimulates SYK autophosphorylation and activation. Also interacts when phosphorylated on Tyr-210 with the SH2 domain of BLNK/SLP65 bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK which is necessary for trafficking of the BCR to late endosomes. Interacts with Src-family tyrosine kinases including FYN and LYN increasing their activity (By similarity).

B-cells.

Defects in CD79A are a cause of non-Bruton type agammaglobulinemia [MIM:601495]. Agammaglobulinemia is an immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Two different mutations one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3 have been identified. Both mutations give rise to a truncated protein.

Contains 1 ITAM domain. Schlossman S. L. Bloumsell W. Gilks J. M. Harlan C. Kishimoto J. Ritz S. Shaw R. Silverstein T. Springer T. F. Tedder and R. F. Todd eds. 1995. Leukocyte Typing V: White Cell Differentiation Antigens Oxford University Press Oxford. Kishimoto T. A. E. G. von dern Borne S. M. Goyert D. Y. Mason M. Miyasaka L. Moretta K. Okumura S. Shaw T. A. Springer K. Sugamura and H. Zola eds. 1998. Leukocyte Typing VI: White Cell Differentiation Antigens Academic Press New York. Barclay A. N. M. H. Brown S. K. A. Law A. J. McKnight M. G. Tomlinson and P. A. van der Merwe eds. 1997. The Leukocyte Antigens Facts Book 2nd Edition CD79 Section Academic Press New York p. 332. Nakamura T. H. Kubagawa and M. D. Cooper 1992. Proc. Natl. Acad. Sci. USA 89:8522.